Teriflunomide for treating relapsing–remitting multiple sclerosis

  • Technology appraisal guidance
  • TA303
  • Published: 
  • Last updated: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the NHS Centre for Reviews and Dissemination and Centre for Health Economics, University of York:

  • Fayter D, Spackman E, Epstein D et al., Teriflunomide for treating relapsing forms of multiple sclerosis, July 2013

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were also invited to comment on the draft scope, the ERG report and the appraisal consultation document. Manufacturers or sponsors were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Genzyme

Professional or specialist and patient or carer groups:

  • Association of British Neurologists

  • Multiple Sclerosis Society

  • Multiple Sclerosis Trust

  • Primary Care Neurology Society

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

  • United Kingdom Multiple Sclerosis Specialist Nurse Association

Other consultees:

  • Department of Health

  • Welsh Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Biogen

The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on teriflunomide by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the appraisal consultation document.

  • Dr Waqar Rashid, Consultant and Honorary Clinical Senior Lecturer in Neurology, Brighton and Sussex University Hospitals NHS Trust, nominated by the Multiple Sclerosis Society - clinical specialist

  • Professor Neil Scolding, Consultant Neurologist, Bristol, nominated by the Association of British Neurologists - clinical specialist

  • Nick Rijke, Director of Policy and Research, the Multiple Sclerosis Society, nominated by the Multiple Sclerosis Society - patient expert

  • Joanne Thomson, nominated by the Multiple Sclerosis Trust - patient expert

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Genzyme

ISBN 978-1-4731-0418-1